Liquid biopsies hold the promise of providing noninvasive, cost-effective and rapid evaluation of circulating tumor DNA (ctDNA) cancer biomarkers. However, biomarker signatures identified in ctDNA are not always concordant with those found in the primary tumor. Thus, discovery and development of robust, reliable ctDNA biomarkers require a detailed study of matched plasma and tumor samples.
Discovery Life Sciences’ sequencing and bioinformatics laboratory, HudsonAlpha Discovery, accelerates cancer biomarker programs by identifying and validating ctDNA biomarkers using high coverage next generation sequencing (NGS) of matched resected tumor tissue and plasma ctDNA. Our research use only (RUO) service leverages highly sensitive TSO500 sequencing assays
